If you go back fifteen or twenty years, the playbook for treating aggressive B-cell lymphomas was pretty simple, remove CHOP or similar cytotoxic combinations right up to the limit of patient tolerance, monitor for severe neutropenic fever during the nadir, and hope the malignant clone succumbed before the organs gave out. Refractory or multiply relapsed cases, the road usually hit a wall fast.
The shift really started gaining momentum when we stopped relying solely on non-specific DNA-damaging agents and began exploiting cell-surface lineage markers. Anti-CD20 monoclonal antibodies like rituximab proved that targeting specific membrane proteins could drive antibody-dependent cellular cytotoxicity without wiping out every rapidly dividing cell in the gut or marrow. Brentuximab vedotin took that a step further by tethering a microtubule-disrupting agent to an anti-CD30 backbone. But surface target recognition was only step one.
Enter PD-1 pathway inhibition. Lymphoma cells routinely overexpress ligands that essentially tell surrounding cytotoxic T-cells to step down. Drugs like nivolumab and pembrolizumab don’t attack the tumour directly; they pull the biological handbrake off exhausted T-cells. In Hodgkin lymphoma, where the Reed-Sternberg cells are surrounded by an immune infiltrate that’s essentially been put to sleep, breaking that signalling axis produces remarkably durable remissions.
Then came bispecific antibodies, agents like mosunetuzumab, glofitamab, and epcoritamab carry two distinct binding arms, one for CD20 on the lymphoma cell and one for CD3 on the T-cell. They literally force an effector cell into direct contact with a target cell, triggering localised cell death regardless of whether the tumour has down-regulated major histocompatibility complex molecules.
Meanwhile, inside the cell, targeted small molecules were changing the game for indolent and aggressive histologies alike. Bruton’s tyrosine kinase inhibitors, ibrutinib, acalabrutinib, zanubrutinib, disrupt chronic active B-cell receptor signalling, effectively starving the cell of its primary survival signal. Combine that with antibody-drug conjugates like loncastuximab tesirine, which internalise and release cross-linking toxins straight into the nucleus, and you get unprecedented precision without systemic exposure.
And then there’s CAR T-cell therapy. Taking autologous T-cells, engineering them with a synthetic receptor against CD19, and reinfusing them created a whole new category of living therapeutics. Products like axicabtagene ciloleucel and tisagenlecleucel transformed outcomes for patients who previously had a median survival measured in months. But CAR-T isn’t a silver bullet for everyone, and toxicity management, specifically cytokine release syndrome and ICANS, demands significant institutional infrastructure.
That’s why multi-agent targeted regimens like ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide). By hitting BCL-2, BTK, immunomodulatory pathways, and surface antigens simultaneously, ViPOR attacks multiple escape routes at once, overcoming single-agent resistance without relying on traditional DNA alkylators.
Moving these strategies into earlier lines of care changes how we run a practice day-to-day. We aren’t just reading PET/CT scans every few cycles anymore; we’re relying heavily on circulating tumour DNA and minimal residual disease (MRD) assays to track molecular response in real time. Conversely, early molecular persistence tells us to pivot long before a physical lesion shows up on a scan. That’s where haematology sits today: less blunt force, far more biological leverage, and a sharp focus on tailored, response-adapted care.
CAR T-cell therapy changed the ceiling entirely. Harvesting a patient’s own T-cells, engineering them to hunt specific antigens, and infusing them back creates a living drug. Products like axi-cel and tisa-cel routinely salvage large B-cell cases that laughed off standard salvage therapies.
Multi-agent schedules like ViPOR hit resistant clones from multiple angles at once. By stacking non-overlapping mechanisms, we finally have the tools to break through resistance pathways and secure durable remissions.
